These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28 related articles for article (PubMed ID: 22157274)
21. Morbidity and mortality in rheumatoid patients during treatment with adalimumab and infliximab. Molloy E; Ramakrishnan S; Murphy E; Barry M Rheumatology (Oxford); 2004 Apr; 43(4):522-3. PubMed ID: 15024136 [No Abstract] [Full Text] [Related]
22. Fatal varicella-zoster virus vasculopathy associated with adalimumab therapy. Baek W; Lee SG; Kim YS; Kim JH; Jun JB; Kim HY Arch Neurol; 2012 Sep; 69(9):1193-6. PubMed ID: 22732856 [TBL] [Abstract][Full Text] [Related]
24. Fatal acquired hemophilia A in a patient with rheumatoid arthritis treated with adalimumab. Arthanari S; Ahmad H; Nisar M J Clin Rheumatol; 2012 Jan; 18(1):50-1. PubMed ID: 22157274 [No Abstract] [Full Text] [Related]
25. Fatal exacerbation of fibrosing alveolitis associated with systemic sclerosis in a patient treated with adalimumab. Allanore Y; Devos-François G; Caramella C; Boumier P; Jounieaux V; Kahan A Ann Rheum Dis; 2006 Jun; 65(6):834-5. PubMed ID: 16699057 [No Abstract] [Full Text] [Related]
26. Camrelizumab-induced immune-related adverse events: Two case reports and literature review. Ge L; Chen W; Zhang G; Wei F Asian J Surg; 2024 Jun; 47(6):2733-2734. PubMed ID: 38522994 [No Abstract] [Full Text] [Related]